OraSure Technologies (OSUR) Aandelenoverzicht
OraSure Technologies, Inc. ontwikkelt, vervaardigt, verkoopt en distribueert samen met zijn dochterondernemingen diagnostische producten en apparatuur voor monsterafname in de Verenigde Staten, Europa, Afrika en internationaal. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 1/6 |
| Toekomstige groei | 0/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 6/6 |
| Dividenden | 0/6 |
Risicoanalyse
Geen risico's gedetecteerd voor OSUR uit onze risicocontroles.
OSUR Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
OraSure Technologies, Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$3.61 |
| 52 Week Hoogtepunt | US$3.82 |
| 52 Week Laag | US$2.08 |
| Bèta | 0.89 |
| 1 maand verandering | 15.71% |
| 3 maanden verandering | 31.27% |
| 1 Jaar Verandering | 43.25% |
| 3 jaar verandering | -26.02% |
| 5 jaar verandering | -62.43% |
| Verandering sinds IPO | -34.36% |
Recent nieuws en updates
Narratiefupdate • May 02
OSUR: Altai Cooperation And Board Changes Will Support Future Upside
Analysts have nudged their price target on OraSure Technologies slightly higher to $4.00, reflecting updated assumptions around the discount rate, modest revenue growth expectations, profit margin adjustments, and a revised future P/E multiple. What's in the News On April 17, 2026, OraSure Technologies entered into a Cooperation Agreement with Altai Capital Management that includes appointing John D.
Narratiefupdate • Apr 18
OSUR: Altai Cooperation Agreement Will Drive Future Upside Potential
Analysts have adjusted their price target on OraSure Technologies to reflect a fair value of $5.00, citing updated assumptions for the discount rate, profit margin, and future P/E ratio as the key drivers of this change. What's in the News On April 17, 2026, OraSure Technologies entered into a Cooperation Agreement with Altai Capital Management, adding John D.Recent updates
Narratiefupdate • May 02
OSUR: Altai Cooperation And Board Changes Will Support Future Upside
Analysts have nudged their price target on OraSure Technologies slightly higher to $4.00, reflecting updated assumptions around the discount rate, modest revenue growth expectations, profit margin adjustments, and a revised future P/E multiple. What's in the News On April 17, 2026, OraSure Technologies entered into a Cooperation Agreement with Altai Capital Management that includes appointing John D.Narratiefupdate • Apr 18
OSUR: Altai Cooperation Agreement Will Drive Future Upside Potential
Analysts have adjusted their price target on OraSure Technologies to reflect a fair value of $5.00, citing updated assumptions for the discount rate, profit margin, and future P/E ratio as the key drivers of this change. What's in the News On April 17, 2026, OraSure Technologies entered into a Cooperation Agreement with Altai Capital Management, adding John D.Narratiefupdate • Apr 01
OSUR: Activist Campaign And Governance Changes Will Support Future Upside
Analysts have made a modest adjustment to their price target for OraSure Technologies to $4.00, reflecting updated assumptions for the discount rate, revenue growth, profit margin, and future P/E multiple. What's in the News Altai Capital Management has escalated its campaign, calling for a broad review of options including a potential sale of OraSure Technologies, criticizing executive pay and board oversight, and urging shareholders to support its director nominees Rishi Bajaj and John Bertrand at the 2026 annual meeting (Investor Activism, March 18, 2026).Narratiefupdate • Mar 18
OSUR: Activist Board Push And Buybacks Will Support Future Upside
Analysts have lifted their price target on OraSure Technologies to $4.00 from $3.00, citing updated expectations regarding revenue growth, profit margins, and a modestly higher future P/E multiple. What's in the News Altai Capital Management sent a letter to OraSure's board on March 17, 2026, outlining a five-pillar case for change, citing share price underperformance, board ownership levels, CEO pay structure, a call for a strategic review, and support for its nominees, Rishi Bajaj and John Bertrand, to join the board (Investor Activism) Altai Capital formally nominated Bajaj and Bertrand for election to the board at the 2026 Annual Meeting and submitted a proposal to declassify the board so all directors stand for annual elections (Investor Activism) OraSure issued first quarter 2026 guidance, projecting total revenues of US$26 million to US$29 million, with only a negligible contribution from COVID 19 testing (Corporate Guidance) The company reported completing a share repurchase of 5,245,180 shares, or 7.12% of its stock, for US$14.89 million under a buyback program announced on March 24, 2025, including 1,900,000 shares bought for US$5 million between October 1 and December 31, 2025 (Buyback Tranche Update) OraQuick HIV Self Test received a Health Canada license as the first oral HIV self test in Canada, offering 20 minute results from an oral swab and distribution through St. Michael's Hospital to support access across healthcare and community settings (Product Related Announcement) Valuation Changes Fair Value: The analyst fair value estimate has risen from $3.00 to $4.00 per share, which represents a material upward revision to the target level.Narratiefupdate • Mar 04
OSUR: New STI Self Testing Submissions Will Drive Future Upside
Analysts have raised their price target on OraSure Technologies from $4.50 to $5.00, citing updated assumptions around revenue growth, profit margin and future P/E that they state better reflect the company’s current outlook. What's in the News OraSure completed a share repurchase tranche between October 1, 2025 and December 31, 2025, buying 1,900,000 shares, or 2.63% of shares, for US$5 million.Narratiefupdate • Feb 18
OSUR: New STI Self Testing Submissions Will Support Future Shareholder Upside
Narrative Update on OraSure Technologies Analysts have kept their OraSure Technologies fair value estimate steady at $4.50, with only marginal tweaks to inputs like the discount rate, long term revenue growth, profit margin, and future P/E assumptions driving this maintained price target. What's in the News OraQuick HIV Self-Test received a Health Canada license, becoming Canada's first oral HIV self test and offering results in about 20 minutes from an oral swab for HIV 1 and HIV 2 antibodies.Narratiefupdate • Feb 04
OSUR: New STI Testing Submissions Will Drive Future Shareholder Value
Analysts have modestly revised their price target for OraSure Technologies to US$4.50, reflecting slightly adjusted assumptions on discount rate, revenue growth, profit margin, and future P/E. These changes leave their overall view of the company’s fair value essentially unchanged.Narratiefupdate • Jan 21
OSUR: At-Home STI Testing Pipeline Will Drive Future Upside
Analysts have maintained their price target on OraSure Technologies at US$3.00. This reflects updated views on factors such as discount rate, revenue growth assumptions, profit margins, and future P/E expectations, while keeping the headline valuation level unchanged.Narratiefupdate • Jan 07
OSUR: At-Home STI Testing And Activist Push Will Drive Future Upside
Analysts have kept their fair value estimate for OraSure Technologies steady at US$3.00 per share, citing largely unchanged assumptions around the company’s discount rate, revenue growth outlook, profit margin profile, and future P/E multiple. What's in the News OraSure submitted two applications to the U.S. FDA at the end of 2025 for clearance of a rapid molecular self-test for Chlamydia trachomatis and Neisseria gonorrhoeae and for its Colli-Pee at-home urine collection device for sexually transmitted infections, both aimed at over-the-counter and at-home use (Key Developments).Narratiefupdate • Dec 23
OSUR: Activist Board Challenge Will Drive Future Shareholder Value Upside
Analysts have reduced their price target on OraSure Technologies from 5.00 dollars to 3.00 dollars per share, citing a higher required return on equity and lower expected future valuation multiples, despite improving revenue growth assumptions and largely stable profit margins. What's in the News Altai Capital Management notified OraSure Technologies Board on December 17, 2025 of its intention to nominate two directors at the 2026 annual meeting, citing share price underperformance and capital allocation concerns (Key Developments).Narratiefupdate • Dec 09
OSUR: Ongoing Share Repurchases Will Drive Future Shareholder Value
Analysts have raised their price target on OraSure Technologies from 4.50 dollars to 4.75 dollars, citing slightly lower discount rate assumptions and a modestly higher long term valuation multiple, despite a small reduction in projected profit margins. What's in the News Completed a share repurchase of 3,345,180 shares, representing 4.49% of outstanding shares, for a total of $9.89 million under the buyback program announced on March 24, 2025 (Key Developments) From July 1, 2025 to September 30, 2025, repurchased 1,524,424 shares, or 2.07% of outstanding shares, for $4.9 million as the latest tranche of the ongoing buyback (Key Developments) Issued fourth quarter 2025 earnings guidance, projecting total revenues of $25 million to $28 million (Key Developments) Q4 2025 outlook includes less than $100,000 in COVID-19 testing revenue, underscoring the company’s pivot away from pandemic-driven sales (Key Developments) Valuation Changes Fair Value Estimate remains unchanged at 4.50 dollars per share, indicating no revision to the intrinsic value assessment.Narratiefupdate • Nov 25
OSUR: Share Buybacks And Board Actions Will Drive Shareholder Value
Narrative Update: Analyst Price Target Adjustment for OraSure Technologies Analysts have reduced OraSure Technologies’ price target from $4.75 to $4.50, citing updated assumptions in growth and profitability metrics. What's in the News OraSure Technologies repurchased 1,524,424 shares for $4.9 million during Q3 2025, completing a total buyback of 3,345,180 shares under the repurchase plan announced in March 2025 (Key Developments).Analyseartikel • Nov 14
Revenues Working Against OraSure Technologies, Inc.'s (NASDAQ:OSUR) Share Price Following 25% Dive
OraSure Technologies, Inc. ( NASDAQ:OSUR ) shares have had a horrible month, losing 25% after a relatively good period...Narratiefupdate • Nov 06
OSUR: Activist Pressure Will Drive Shareholder Value Amid Board Challenge
Analysts have revised their price target for OraSure Technologies from $6.00 to $4.75, citing updated projections for revenue growth and broader shifts in valuation estimates. What's in the News Healthcare entrepreneur Ron Zwanziger warned OraSure that he may pursue an adversarial strategy if the company continues to resist his acquisition bid, following OraSure's rejection of his all-cash offer earlier this summer (Reuters).Analyseartikel • Aug 08
OraSure Technologies, Inc. (NASDAQ:OSUR) Analysts Are Pretty Bullish On The Stock After Recent Results
There's been a notable change in appetite for OraSure Technologies, Inc. ( NASDAQ:OSUR ) shares in the week since its...Seeking Alpha • Jul 28
OraSure Technologies: An Asymmetric Bet
Summary OraSure trades near cash value with minimal debt, reflecting excessive market pessimism and creating an asymmetric risk-reward opportunity. The company's future hinges on Sherlock's at-home STD test kit, with a high probability of FDA approval and strong market potential. Management is actively streamlining operations, divesting non-core assets, and positioning OraSure as an attractive acquisition target. Downside risk is limited by a strong balance sheet and buyback program, while acquisition or Sherlock's success could drive significant upside. Read the full article on Seeking AlphaAnalyseartikel • May 08
Shareholders Will Probably Hold Off On Increasing OraSure Technologies, Inc.'s (NASDAQ:OSUR) CEO Compensation For The Time Being
Key Insights OraSure Technologies will host its Annual General Meeting on 14th of May Total pay for CEO Carrie Eglinton...Analyseartikel • Feb 27
Investors Don't See Light At End Of OraSure Technologies, Inc.'s (NASDAQ:OSUR) Tunnel And Push Stock Down 26%
OraSure Technologies, Inc. ( NASDAQ:OSUR ) shareholders won't be pleased to see that the share price has had a very...
Nieuw narratief • Feb 09
Launch Of OraQuick HCV Self-Test And Genomics Ventures Will Open Markets Amid Profitability Pressures
The international launch of the OraQuick HCV Self-test and upcoming blood proteomics launch offer significant revenue and growth opportunities.Seeking Alpha • Dec 11
OraSure Technologies: Discounted Assets With An Attractive Free Call Option
Summary OraSure Technologies is undervalued, trading below its net current asset value, offering a compelling risk-reward scenario with limited downside risk. The company has a robust balance sheet with no long-term debt and $280 million in cash, mitigating downside risks. Post-COVID margins are expected to improve, driving positive cash flow and substantial upside potential, with a projected 70%+ appreciation. Management is competent and aligned with shareholders, enhancing confidence in the company’s ability to capitalize on its undervaluation. Read the full article on Seeking AlphaAnalyseartikel • Nov 14
Some May Be Optimistic About OraSure Technologies' (NASDAQ:OSUR) Earnings
Shareholders appeared unconcerned with OraSure Technologies, Inc.'s ( NASDAQ:OSUR ) lackluster earnings report last...Analyseartikel • Nov 08
Here's What Analysts Are Forecasting For OraSure Technologies, Inc. (NASDAQ:OSUR) After Its Third-Quarter Results
OraSure Technologies, Inc. ( NASDAQ:OSUR ) just released its third-quarter report and things are looking bullish...Seeking Alpha • Nov 04
OraSure: An NCAV Diamond In The COVID Rough
Summary OraSure Technologies Inc. is a health and wellness company specializing in "easy to use" diagnostic and specimen collection products. OraSure has a strong balance sheet and is trading below its net current asset value. At the same time, OraSure has a stable operational history with consistent normalized cash flow margins. OraSure has the potential to return to its (much higher) historical NCAV multiples, particularly when considering the new management teams' focus on operational efficiency through cost control. Read the full article on Seeking AlphaSeeking Alpha • Sep 10
OraSure Technologies: Nursing A COVID-19 Hangover
Summary Today, we revisit OraSure Technologies, Inc., a diagnostic firm that, like many in the industry, is going through a post-COVID hangover. The good news for the company is it is sitting on a huge cash balance and management is doing a good job of reducing operating expenses. An updated analysis around OraSure Technologies follows in the paragraphs below. Read the full article on Seeking AlphaAnalyseartikel • May 11
OraSure Technologies, Inc. (NASDAQ:OSUR) Just Reported Earnings, And Analysts Cut Their Target Price
It's been a sad week for OraSure Technologies, Inc. ( NASDAQ:OSUR ), who've watched their investment drop 11% to...Analyseartikel • Apr 17
Lacklustre Performance Is Driving OraSure Technologies, Inc.'s (NASDAQ:OSUR) Low P/S
With a price-to-sales (or "P/S") ratio of 1x OraSure Technologies, Inc. ( NASDAQ:OSUR ) may be sending very bullish...Analyseartikel • Mar 01
Earnings Beat: OraSure Technologies, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
It's been a good week for OraSure Technologies, Inc. ( NASDAQ:OSUR ) shareholders, because the company has just...Analyseartikel • Feb 29
Return Trends At OraSure Technologies (NASDAQ:OSUR) Aren't Appealing
What are the early trends we should look for to identify a stock that could multiply in value over the long term...Analyseartikel • Dec 20
OraSure Technologies, Inc.'s (NASDAQ:OSUR) Business And Shares Still Trailing The Industry
OraSure Technologies, Inc.'s ( NASDAQ:OSUR ) price-to-sales (or "P/S") ratio of 1.3x might make it look like a buy...Rendement voor aandeelhouders
| OSUR | US Medical Equipment | US Markt | |
|---|---|---|---|
| 7D | 20.3% | 4.4% | 1.0% |
| 1Y | 43.3% | -17.9% | 28.7% |
Rendement versus industrie: OSUR overtrof de US Medical Equipment industrie, die het afgelopen jaar een rendement -17.9 % opleverde.
Rendement versus markt: OSUR overtrof de US markt, die het afgelopen jaar een rendement opleverde van 28.7 %.
Prijsvolatiliteit
| OSUR volatility | |
|---|---|
| OSUR Average Weekly Movement | 7.0% |
| Medical Equipment Industry Average Movement | 8.7% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiele aandelenkoers: OSUR heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 7% ) van OSUR is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1987 | 500 | Carrie Eglinton Manner | www.orasure.com |
OraSure Technologies, Inc. ontwikkelt, vervaardigt, verkoopt en distribueert samen met zijn dochterondernemingen diagnostische producten en apparatuur voor monsterafname in de Verenigde Staten, Europa, Afrika en internationaal. Het bedrijf biedt OraQuick snelle hiv-test, OraQuick hiv-zelftest, OraQuick hiv-zelftest (internationaal), OraQuick HCV snelle antilichaamtest en zelftest, Syfilis health check snellediagnosetest, OraQuick Ebola snelle antigeentest, InteliSwab COVID-19 snelle test, InteliSwab COVID-19 snelle test pro, InteliSwab COVID-19 snelle test rx, SickleSCAN-test en OraSure apparaat voor het verzamelen van oraal vocht voor hiv-1-antilichamen; Intercept drugs testsystemen; immunoassay tests en reagentia; en Q.E.D. speeksel alcoholtest. Het bedrijf levert ook genomische producten onder de merknamen Oragene en ORAcollect voor het verzamelen van genetisch materiaal uit menselijk speeksel; Colli-Pee-afnameapparaten voor het volumetrisch verzamelen van urinemonsters; en HEMAcollect-apparaat voor het verzamelen van proteïnebloed.
OraSure Technologies, Inc. Samenvatting
| OSUR fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$226.51m |
| Inkomsten(TTM) | -US$75.07m |
| Inkomsten(TTM) | US$113.02m |
2.2x
P/S-verhouding-3.3x
Koers/WinstverhoudingIs OSUR overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| OSUR resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$113.02m |
| Kosten van inkomsten | US$65.25m |
| Brutowinst | US$47.77m |
| Overige uitgaven | US$122.84m |
| Inkomsten | -US$75.07m |
Laatst gerapporteerde inkomsten
Mar 31, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -1.09 |
| Brutomarge | 42.27% |
| Nettowinstmarge | -66.42% |
| Schuld/Eigen Vermogen Verhouding | 0% |
Hoe presteerde OSUR op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/05/22 13:14 |
| Aandelenkoers aan het einde van de dag | 2026/05/22 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
OraSure Technologies, Inc. wordt gevolgd door 15 analisten. 2 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Charley Jones | Barrington Research Associates, Inc. |
| Karen Koski | BTIG |
| Mark Massaro | Canaccord Genuity |